Poorly performing antibodies have plagued biomedical sciences for decades. Several fresh initiatives hope to change this.

A major limitation, Daskalakis said, is that the surveys were conducted an average of 49 days after the first exposure ...

A new human skin atlas and skin organoid could revolutionize treatments for skin disorders and enhance regenerative medicine ...

Diadem SpA, in partnership with researchers from the University of Texas Medical Branch, led by Prof. Rakez Kayed from the ...

Advancing investigation of [212Pb]VMT01 as a monotherapy and in combination with the anti-PD-1 antibody, nivolumab, in patients with previously ...

NextCure (NXTC) reported pre-clinical data from LNCB74, a B7-H4-targeting antibody-drug conjugate, or ADC, being developed in partnership with ...

But despite causing major disease, these slightly mutated proteins can resemble their normal ... from the antibody binding even less to mouse wild-type HER2 than to the human version.

Two examples of the Company’s speed advantage resulting from its internal innovation at scale: CDK4i entered the clinic in ...

Using a U-p53AZ-specific antibody developed by Diadem, the team identified the presence of this misfolded protein in human brain tissue ... p53 misfolding from normal p53 conformations.

Department of Physiology, Harold Hamm Diabetes Center, The University of Oklahoma Health Science Center, Oklahoma City, United States ...